L-pampo / CHA Vaccine Institute - LARVOL DELTA

Cha Baek-shin-yeon, anticancer vaccine utilizing immune booster 'El-Pampo', registered with Japanese patent [Google translation] (HIT News) - "Cha Vaccine Research Institute, a subsidiary of Cha Biotech, announced on the 20th that it has acquired a Japanese patent for an anticancer vaccine composition and manufacturing method utilizing the immune booster 'L-pampo' developed by the company....In addition, it announced plans to continuously expand patent registration in global markets including Japan and accelerate the development of anticancer vaccines and immuno-oncology drugs."

Patent • Oncology

Comparative network-based analysis of toll-like receptor agonist, L-pampo signaling pathways in immune and cancer cells. (PubMed, Sci Rep) - "This signal flow may further sensitize prostate cancer to L-pampo due to its high basal expression level of OXPHOS and ROS. Our computational approaches can be applied for inferring underlying molecular mechanisms from complex gene expression profiles."

IO biomarker • Journal • Genito-urinary Cancer • Infectious Disease • Oncology • Prostate Cancer • Solid Tumor

L-pampo™, a TLR2/3 agonist, enhances anti-tumor immune responses and synergistically improves the anti-tumor efficacy of immune checkpoint inhibitors in cold tumors (AACR 2024) - "To compare the anti-tumor efficacy of L-pampo and conventional cytotoxic chemotherapy, we treated tumor-bearing mice with FOLFOX or paclitaxel as SoC regimen, respectively... This study suggests that L-pampo, a novel TLR2/3 agonist, can be a potent anti-tumor agent, improving the anti-tumor efficacy of ICIs in cold tumors with enhanced anti-tumor immunity and minimal toxicities than conventional chemotherapies."

Checkpoint inhibition • Clinical • Breast Cancer • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • TLR2

L-Pampo™, a Novel TLR2/3 Agonist, Acts as a Potent Cancer Vaccine Adjuvant by Activating Draining Lymph Node Dendritic Cells. (PubMed, Cancers (Basel)) - "Moreover, the combination of L-pampo™ with an immune checkpoint inhibitor synergistically improved the anti-tumor effect. This study suggests that L-pampo™ can be a potent cancer vaccine adjuvant and a suitable candidate for combination immunotherapy."

IO biomarker • Journal • Infectious Disease • Oncology • TLR2

CHA Vaccine Institute confirms effectiveness of immune-cancer drug candidate L-pampo (Korea Biomedical Review) - "CHA Vaccine Institute said Monday it has confirmed the immuno-cancer treatment effect of L-pampo, an immuno-cancer drug candidate that stimulates the toll-like receptor (TLR) signal pathway, developed by the institute independently....When L-pampo was administered alone to a colorectal cancer mouse model, the tumor size decreased by 57.2 percent in the L-pampo administration group, and CD8+ T cells attacking cancer cells increased by 5.2 times....In the colorectal cancer mouse model, L-pampo activated systemic anticancer immune responses, showing 65.9 percent tumor suppression effect compared to 52.5 percent without administration."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. (PubMed, J Immunother Cancer) - "Our study demonstrated that intratumoral LP treatment improves the innate and adaptive antitumor immunity within the TME and enhances the efficacy of αPD-1 and αCTLA-4 immune checkpoint blockade."

Checkpoint inhibition • IO biomarker • Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Immune Modulation • Inflammation • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • CTLA4 • IFNG • IL2RA

COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity. (PubMed, Vaccines (Basel)) - "Furthermore, in the ferret model, SARS-CoV-2 antigens with L-pampo elicited nAb response and antigen-specific cellular immune response against SARS-CoV-2, resulting in substantially decreased viral load in their nasal wash. Our study suggests that SARS-CoV-2 antigens formulated with TLR agonists, L-pampo, can be a potent subunit vaccine to promote sufficient protective immunity against SARS-CoV-2."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

[VIRTUAL] Intratumoral immunotherapy with a novel TLR1/2/3 agonist, L-pampo, induces robust anti-tumor immune responses and enhances immune checkpoint blockade (ESMO 2021) - "Overall, our study demonstrated that intratumoral immunotherapy with L-pampo elicits strong anti-tumor immunity within the tumor microenvironment and strengthens the efficacy of immune checkpoint blockade."

Checkpoint inhibition • Bladder Cancer • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Oncology • Pancreatic Cancer • Solid Tumor • Urothelial Cancer • CD4 • CD8 • FOXP3 • IFNG • IL2RA